Tailored menopause care for breast cancer survivors addresses hormone therapy challenges, emphasizing individualized care and shared decision-making for high-risk patients. The SERENA-6 trial ...
Avan Armaghani, MD, reviews three key topics in the management of hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer to be explored at this year’s ...
Dr Harold J. Burstein of the Dana-Farber Cancer Institute, Boston, highlights key ER+ breast cancer abstracts from the 2025 San Antonio Breast Cancer Symposium. Beginning with the metastatic setting, ...
From smart pill bottles that help people remember to take their meds to calls for better menopausal symptom relief for women with breast cancer to intriguing hints at what drives dormant tumor cells ...
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage ...
New York, NY (December 8, 2025) – Researchers and clinicians from the Icahn School of Medicine at Mount Sinai will present new discoveries in breast cancer biology, treatment, and real-world patient ...
SurvivorNet on MSN
SurvivorNet brings powerful survivor voices to the 2025 San Antonio Breast Cancer Symposium
At the San Antonio Breast Cancer Symposium (SABCS), a leading global forum for breast cancer research, SurvivorNet brought ...
NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results